DRD1 and Parkinson disease: Therefore we posit that the D1R–D2R heteromer may mediate, at least in part, the therapeutic effects of L-dopa, but not the deleterious side effects induced by this treatment, implicating this receptor complex as a valid novel therapeutic target in Parkinson's disease.